A patient with crepey infraorbital skin, early laxity and a preference for natural change does not need the latest injectable trend. They need a diagnosis, a realistic discussion of biology and a treatment plan that respects the anatomy. That is why the question of PRP versus polynucleotides cannot be answered by asking which product is ‘better’. These are different regenerative approaches, with different biological signals, practical demands and evidence bases.
For clinicians, the decision should sit within a medically led framework: skin quality, degree of photodamage, vascularity, inflammation, volume loss, lifestyle factors and the patient’s tolerance for downtime all matter. For patients, the most useful distinction is simpler. Neither treatment is a substitute for a properly indicated toxin, filler, energy-based procedure or surgical referral. Their value lies primarily in improving tissue quality over time.
PRP versus polynucleotides: the biological distinction
Platelet-rich plasma, usually abbreviated to PRP, is an autologous preparation produced from the patient’s own blood. Following venepuncture and centrifugation, a platelet-enriched fraction is prepared and injected or used in selected microneedling protocols. Platelets contain signalling molecules involved in wound repair, including growth factors that influence fibroblast activity, angiogenesis and extracellular matrix remodelling.
The attraction of PRP is clear: it is derived from the individual being treated. When appropriately prepared and administered, it offers a biologically plausible method of supporting repair processes without introducing a synthetic volumising material. However, PRP is not one standardised treatment. Platelet concentration, leucocyte content, activation technique, centrifuge system, blood handling, injection plane and treatment interval can all vary. A paper reporting benefit from one preparation cannot automatically be applied to every PRP protocol.
Polynucleotides are purified DNA fragments, commonly derived from fish sources, formulated as injectable devices or products depending on the market and regulatory classification. Their proposed action is different from PRP. Rather than delivering platelets, polynucleotides are used to support the extracellular environment, tissue hydration and reparative cellular activity. Preclinical and early clinical literature suggests effects on fibroblast function, collagen-related pathways and inflammatory modulation, but the exact clinical significance depends on the formulation and indication.
In practice, polynucleotides are often selected for fragile, dehydrated or photodamaged skin, especially where a clinician wishes to improve texture and elasticity without adding conventional filler volume. Their rheology is usually soft, and their role is regenerative rather than structural.
What each treatment can reasonably achieve
The language surrounding regenerative injectables needs discipline. Neither PRP nor polynucleotides should be presented as a guaranteed reversal of ageing, nor as a replacement for volume restoration where true deflation is the principal problem.
PRP may be considered for dull skin, fine textural change, selected acne scarring protocols, scalp concerns and early age-related skin change. Some practitioners favour it in patients who strongly prefer autologous treatment, or where there is an established indication within a broader skin-restoration programme. Its effects, when seen, are typically gradual: improved luminosity, a healthier surface quality and modest change in fine lines rather than a dramatic alteration in facial shape.
Polynucleotides may be particularly useful where skin is thin, crepey or showing reduced resilience. The periorbital region, neck, décolletage and hands are frequently discussed, although each area presents specific anatomical and safety considerations. In the tear trough, for example, the desire to avoid traditional hyaluronic acid filler does not remove the need for careful patient selection. Pigmentation, herniated fat, oedema, ligamentous change and skeletal support must still be assessed.
The important clinical question is not whether PRP or polynucleotides are regenerative. It is whether the patient’s concern is primarily one of skin quality. A patient seeking improvement in etched dynamic lines may require neuromodulation. A patient with significant lower-face descent may benefit more from a surgical opinion than repeated injectable sessions. Regenerative treatment is strongest when it is not asked to perform a structural task.
Evidence: promising, but not interchangeable
The evidence for both modalities is evolving. PRP has a longer history of clinical use across several medical fields, including musculoskeletal medicine and hair restoration, although findings in aesthetic skin rejuvenation remain complicated by protocol variation. Study populations are often small, assessment tools differ and outcomes such as ‘skin quality’ can be subjective.
Polynucleotides have generated increasing interest in European aesthetic practice, particularly for skin revitalisation. Yet the published literature also requires measured interpretation. Product-specific data, small cohorts, variable comparators and relatively short follow-up are common limitations. Biological plausibility is valuable, but it is not the same as proof of a uniform outcome across all products, facial areas and patient groups.
For an evidence-informed practice, this has practical consequences. Clinicians should explain the degree of uncertainty, use validated photography where appropriate and avoid promising collagen regeneration as though it were immediately visible or precisely quantifiable in every individual. Treatment plans should be reviewed against outcomes, not defended because a protocol has become fashionable.
Safety begins before the injection
Both procedures are often described as minimally invasive. That description should never imply risk-free. With PRP, bruising, swelling, tenderness and temporary inflammatory response are common practical considerations. The procedure also involves blood collection and preparation, so aseptic technique, training, equipment maintenance and clear handling protocols are fundamental.
Polynucleotide injections can similarly produce transient erythema, swelling, bruising and visible papules depending on the technique and product. As with all injectables, infection, hypersensitivity, vascular events and poor aesthetic outcomes must be addressed in consent discussions, even if the probability of a serious complication is low. Treatment around the eye requires particular expertise because the anatomy is unforgiving and oedema can be difficult to manage.
A comprehensive medical history remains essential. Active infection, uncontrolled inflammatory dermatoses, relevant anticoagulant use, pregnancy or breastfeeding, immune conditions, previous adverse reactions and unrealistic expectations may alter the decision to treat or delay treatment. For PRP, platelet disorders and medications that affect platelet function merit careful consideration. For polynucleotides, product constituents, source material and manufacturer guidance should be reviewed rather than assumed.
The safest clinic is not the clinic that says every patient is suitable. It is the clinic that can explain why treatment is deferred, modified or replaced by a more appropriate option.
Choosing between PRP and polynucleotides
There are situations in which a preference may be reasonable. A patient who values an autologous approach and is comfortable with venepuncture may favour PRP. Someone with marked skin fragility or dehydration, who does not require volume, may be a suitable candidate for a polynucleotide protocol. A clinician may also choose one modality based on the anatomical area, previous response, available evidence for the intended use and the patient’s ability to attend a course of treatment.
However, neither choice should be reduced to a single consultation-room rule. PRP outcomes may be influenced by the patient’s baseline health, smoking status, age, blood parameters and preparation method. Polynucleotide outcomes depend on product selection, placement, dosing schedule and the quality of the surrounding skin-care and photoprotection programme.
Combination treatment can be appropriate, but combination for its own sake is not sophisticated medicine. PRP or polynucleotides may sit alongside prescription skincare, pigment management, microneedling, lasers, radiofrequency or carefully selected injectables. Sequencing matters. Inflamed, barrier-impaired or excessively treated skin should be stabilised before more procedures are added.
A consultation should lead the protocol
At Professor Patrick Treacy’s level of regenerative aesthetic practice, the standard is not simply to offer a procedure. It is to establish a defensible clinical rationale. This includes baseline photographs, assessment of facial movement and tissue support, discussion of treatment alternatives, clear consent and a defined review point.
Patients should also be prepared for incremental outcomes. Both PRP and polynucleotides are generally undertaken as a course, with maintenance determined by response rather than a fixed commercial timetable. Visible improvement may emerge over weeks, while collagen-related remodelling, where it occurs, takes longer. Good skin health also depends on daily ultraviolet protection, smoking cessation where relevant, adequate nutrition and management of dermatological disease.
For clinicians, protocol discipline protects patients and strengthens the field. Record the PRP preparation method, product batch details, injection technique, volumes, anatomical sites, adverse events and standardised outcome measures. This is not administrative excess. It is how regenerative medicine moves from anecdote towards accountable clinical practice.
The most useful choice between PRP and polynucleotides is therefore the one made after diagnosis, not before it. When regenerative injectables are used with restraint, anatomical understanding and honest expectations, they can support healthier-looking tissue without compromising the principles of patient safety or long-term care.